Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research by unknown
Mikdashi and Nived Arthritis Research & Therapy  (2015) 17:183 
DOI 10.1186/s13075-015-0702-6REVIEW Open AccessMeasuring disease activity in adults with
systemic lupus erythematosus: the challenges
of administrative burden and responsiveness
to patient concerns in clinical research
Jamal Mikdashi1* and Ola Nived2Abstract
Measuring lupus disease activity accurately remains a challenging and demanding task given the complex multi-system
nature of lupus, an illness known for its variability between patients and within the same patient over time. Many have
attempted to define what disease activity means and how it should be measured, and several instruments were devised
for a standardized assessment of disease activity and outcome domains in clinical research. Several of these measuring
tools have been able to detect clinical improvement and have demonstrated adequate reliability, validity, and sensitivity
to change in observational studies, and some were found to be useful in randomized controlled trials. However, several
failed clinical trials have confronted these metrics, as they were not intended for clinical trials. The Outcome Measures
Rheumatology group and the US Food and Drug Administration have recommended using measures of disease activity,
cumulative organ damage, health-related quality of life, and adverse events as outcomes of interest. Composite responder
indices that determine disease global improvement, ensure no significant worsening in unaffected organ systems,
and include a physician’s global assessment have been used in randomized clinical trials. Yet unmet therapeutic
needs were further challenged by the complex content and psychometric information of the updated instruments,
including increased administrative burden associated with demanding training and cost of instruments, and small
effect size associated with responsiveness to patient concerns. Nevertheless, with the progress of novel targeted
therapy, refining the disease activity metrics is essential. Selection of the disease activity endpoints which is a defining
aspect of clinical trial design must be tailored to the outcome of interest and measured by a reliably rated scale
characterized by minimal administrative burden. An optimal scale should be simple and practical and incorporate
elements of patient concerns.Measurement of disease activity in systemic lupus ery-
thematosus (SLE) is central to clinical research when
evaluating clinical outcomes, comparing meaningful dif-
ferences among SLE patient groups, and assessing dis-
ease activity longitudinally for observational and clinical
trials. Several reliable and validated instruments have
been available since the early 1980s, and some updated
measures are now being used in clinical trials for classi-
fying and monitoring groups of patients and gauging re-
sponses to a new drug [1–8]. The administrative burden* Correspondence: jmikdash@umaryland.edu
1Division of Rheumatology and Clinical Immunology, University of Maryland
School of Medicine, 10 South Pine Street, Suite 834, Baltimore, MD 21201,
USA
Full list of author information is available at the end of the article
© 2015 Mikdashi and Nived. This is an Open A
License (http://creativecommons.org/licenses/
medium, provided the original work is proper
creativecommons.org/publicdomain/zero/1.0/of the current versions of these tools, their psychometric
properties, and how much they are responsive to patient
concerns still have not been well addressed.
The complex nature of SLE with fluctuating levels of
disease activity involving one or multiple organs, which
may vary between patients and within the same patient
over time, continues to challenge SLE investigators. The
absence of a ‘gold standard’ for defining disease activity,
and the diverse psychometric properties of each pro-
posed scale contributes to the difficulty when refining
these tools. The inter-rater variability in the assessment
of disease activity confronts even an experienced evalu-
ator or a well-trained investigator. The predictability of
detecting a substantial meaningful change is far moreccess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
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) applies to the data made available in this article, unless otherwise stated.
Mikdashi and Nived Arthritis Research & Therapy  (2015) 17:183 Page 2 of 10challenging than the complexity encountered when using
the instrument itself [9, 10]. The administrative burden of
the disease activity measure with its intricate psychometric
properties needs to be taken into consideration when
choosing an instrument applicable in a particular research
or clinical setting. The administrative burden expands be-
yond the knowledge about the instrument itself to include
the preparedness and skillfulness of the assessor, the mode
of administration, the time required to complete the in-
strument, and the complexity of scoring. Furthermore, the
varied length of the scales (number of items and scoring
scale), number of patients included, or disease severity of
patients under study influence the performance across
proposed instruments and weigh into the administrative
burden through required advanced training and familiarity
of the instrument.
The Outcome Measures Rheumatology group and the
US Food and Drug Administration (FDA) had recom-
mended using measures of disease activity, cumulative
organ damage, health-related quality of life (HRQOL),
and adverse events as outcomes of interest [11].
Patient-reported outcome measures broadly classified
as descriptive, discriminative, evaluative, or predictive
or a combination of these are being incorporated in
clinical trials yet still await further adaptation and val-
idation to reflect an accurate measure of any interven-
tion. Responsiveness remains a key element of the
psychometric properties of any instrument. It is pivotal
to identify and validate appropriate global, disease-specific,
and perhaps organ-specific health-related outcomes for
clinical research.
This article reviews the commonly used disease activ-
ity tools and discusses: (a) strengths and weaknesses of
each of the disease activity measures and responder indi-
ces, with an emphasis on the psychometric properties;
(b) the administrative burden and cost of training; and
(c) how much each tool is capable of capturing respon-
siveness to patient concerns. A summary of several dis-
ease activity indices is depicted in Table 1. The article
concludes with recommendations on the optimal disease
activity measures and responder index research tool
along with a set of practical suggestions for developing a
research agenda for detecting meaningful outcome in
lupus research.
Major disease activity measures
British Isles Lupus Assessment Group (BILAG) index and
BILAG-2004
The BILAG index, an organ-based transitional activity
instrument, provides disease activity scorings across
eight organ systems on an ordinal scale (A to E) based
on the physician’s intention-to-treat premise [3]. The
original version was published in 1988, and the updated
version (BILAG-2004) was published in 2005. In therevised index, the original section of vasculitis was re-
moved and two systems were added: ophthalmic and
abdominal.
The BILAG-2004 index categorizes disease activity
into five different levels from A to E. Grade A represents
very active disease likely necessitating immunosuppressive
drugs and/or a prednisolone (or equivalent) dose of more
than 20 mg daily or high-dose anticoagulation. Grade B
represents moderate disease activity requiring a lower
dose of corticosteroids, topical steroids, topical immuno-
suppressive drugs, anti-malarials, or non-steroidal anti-
inflammatory drugs. Grade C indicates mild stable disease,
and grade D implies no disease activity but suggests the
system had previously been affected. Grade E indicates no
current or previous disease activity.
BILAG records disease activity occurring over the past
4 weeks. The BILAG-2004 index covers 97 items, and
the classic BILAG index contains 86 items. Each question
is answered as 0 = not present, 1 = improving, 2 = same,
3 = worse, or 4 = new. The BILAG-2004 system tally
provides a disease activity measure that scores longitudin-
ally and is clinically meaningful and easier to analyze in
comparison with multiple categorical variables. It has three
components (systems with active/worsening disease, sys-
tems with improving disease and systems with persistent
minimal or no activity). This system has expected associa-
tions with change in therapy.
This allows not only detection of changes across differ-
ent organs but also differentiation of major from minor
improvement or (where relevant) deterioration, combin-
ing the simplicity of numerical scoring with the clinical
intuitiveness of the BILAG-2004 categorical scoring [12].
The British Lupus Integrated Prospective System
(BLIPS) is a computerized program that calculates the
BILAG scores [3].Psychometric information
The classic BILAG and BILAG-2004 have been found
to be reliable, valid, and sensitive to change over time
and have correlated with other disease activity mea-
sures (in particular, the Systemic Lupus Erythematosus
Disease Activity Index, or SLEDAI) [13, 14]. Good reli-
ability (intraclass correlation coefficient (ICC) of more
than 0.60), high levels of physician agreement (σphysician/
σpatient of less than 0.40), and inter-rater reliability of the
index with overall ICCs of 0.45 (95 % confidence interval
(CI) 0.31 to 0.58) and 0.67 (95 % CI 0.54 to 0.76) have
been demonstrated [15]. The overall sensitivity of the
index has been determined at 81 %, specificity at 81.9 %,
positive predictive value at 56.8 %, and negative predictive
value at 93.6 %. Construct and criterion validity have been
verified. The BILAG-2004 systems tally requires further
validation.
Table 1 Systemic lupus erythematosus disease activity measurements and their psychometric properties, administrative burden, and
responsiveness to patient concerns
SLE disease activity
measure
Psychometric properties Administrative burden Responsiveness to patient care
BILAG and BILAG-2004 Reliable, valid, and sensitive to small change
over time
A computer is needed. Responsive
Laboratory studies are required. Fibromyalgia syndrome may complicate
the assessment of lupus disease activity.





Weakness: Formal training is essential for
optimal performance.
commercial/academic
SLAM and SLAM-R Reliable, valid, sensitive, and responsive to
change over time
A physician is to complete history
and physical.
Highly responsive
Strength: includes both disease activity and
severity
Laboratory studies are needed.
Time: 15 minutes
Weakness: subjective scoring by patients Training is required.
Cost: $
commercial/academic
SLEDAI, SELENA-SLEDAI Reliable, valid, sensitive, and responsive to
change over time




Strength: practical, most commonly used for
clinical and research purposes
Laboratory studies are needed.
(There are no immunologic tests
for the Mexican version.)
Weakness: The SLEDAI versions do not capture
improving or worsening and do not include





SLE Responder Index (SRI) Reliable and valid A physician is to complete history
and physical.
Modest responsiveness
Strength: SRI-50 is superior to the SLEDAI-2 K
in identifying patients with 50 % or greater
improvement.
SRI-50 Laboratory studies are needed.
Time: 15 minutes
Training is required.






Reliable and valid A physician is to complete history
and physical.
Responsive
Strength: focused response criteria
Lupus nephritis outcome
measure
Weakness: Defining the optimal endpoint of
organ-specific response criteria is needed.
Laboratory studies are needed.
Time: 30 minutes






Reliable and valid A physician is to complete history
and physical.
Responsive
Strength: BICLA criteria require a stringent
response in all body systems that are
involved at baseline and require that there
be no new flares in the remaining body
system.




commercial/academicWeakness: Formal training is essential for
optimal performance.
Mikdashi and Nived Arthritis Research & Therapy  (2015) 17:183 Page 3 of 10
Table 1 Systemic lupus erythematosus disease activity measurements and their psychometric properties, administrative burden, and
responsiveness to patient concerns (Continued)
SELENA-SLEDAI Flare
Index (SFI)
Reliable and valid A physician is to complete history
and physical.
Responsive
Strength: The revised SFI suggests specific
clinical manifestations for each organ system
and categorizes flares into mild, moderate,
and severe on the basis of the treatment
decision.




commercial/academicWeakness: Training is essential for optimal
performance.
BILAG-2004 flare index Reliable and valid A physician is to complete history
and physical.
Moderate responsiveness
Strength: A strict criterion is needed to define
flare. Laboratory studies are needed.
Weakness: Scoring of worsening in the renal





Lupus Foundation flare Strength: The flare must be considered clinically
significant by the assessor.
A physician is to complete history
and physical.
Responsive
Weakness: The emphasis is on clinical judgment
in determining flare significance.




A strict intention to treat is required. commercial/academic
BILAG, British Isles Lupus Assessment Group; CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index; SELENA-SLEDAI, Safety of Estrogens in Lupus
National Assessment-Systemic Lupus Erythematosus Disease Activity Index; SLAM, Systemic Lupus Activity Measure; SLAM-R, Systemic Lupus Activity Measure-Revised; SLE,
systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SLEDAI-2 K, Systemic Lupus Erythematosus Disease Activity Index 2000; SRI-50,
SLEDAI-2000 Responder Index 50.
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important element of change in disease state with time. It is
sensitive to small changes and distinguishes between dis-
ease activity and disease severity. It shows disease activity in
individual systems ‘at a glance’ rather than combining them
into a global score. Despite the complex calculations, the
score is quick to conduct, especially when calculated by a
computer, and is only minimally dependent on the particu-
lar clinician carrying out the procedure. The numerical
scoring system facilitates comparisons with global indices
by converting the assessments so that ‘A’ = 12 points, ‘B’ = 8
points, ‘C’ = 1 point, and ‘D/E’ = 0 points [16].
Weakness Formal training of raters and a well-defined
glossary are essential to ensure the optimal performance
and achieve a valid registration of the index. Despite the
high physician agreement in almost all systems, inter-
rater validity continues to be superior among the BILAG
group compared with other trained researchers.
Administrative burden BILAG is completed by a phys-
ician. A computer program is needed to calculate cat-
egorical or numerical scoring. In addition to the time
spent on complete history and physical examination,BILAG requires up to 50 minutes to administer, and the
instrument cannot be scored until laboratory results are
available, and this may take a few days. There is no cost
to use the BILAG instrument unless the computerized
version is needed; the cost then depends upon type of
usage (commercial/academic).
Responsiveness to patient concerns Major clinical re-
sponses by the BILAG index are a BILAG C score or
better at 6 months with no new BILAG A or B scores
and the maintenance of response with no new BILAG A
or B scores between 6 and 12 months. It should be
noted that sleep disorders, depression and fibromyalgia
may confound the assessment of lupus disease activity
when using the BILAG. With the exception of the mu-
cocutaneous, hematologic, and renal domains, a signifi-
cant relationship of the individual BILAG component
scoring with Medical Outcome Study Short Form SF20+
measured global assessment of patient well-being and
health status has been demonstrated.
Systemic lupus activity measure
The Systemic Lupus Activity Measure (SLAM) index,
published in 1988 and revised in 1991, measures global
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oped on the basis of domain sampling theory. Items
chosen for the scale represent those manifestations that
occur more frequently, can be graded, and can be oper-
ationally defined and reliably rated [17].
Systemic Lupus Activity Measure-Revised (SLAM-R)
includes 23 clinical manifestations in nine organs/sys-
tems and seven laboratory features and has a possible
range of 0 to 81; a score of at least 7 is considered clinic-
ally important because it is associated with a probability
of initiating therapy in more than 50 % of cases. Each
organ item may score 0 to 3 points if any of the said
organ’s
> clinical manifestations were present within the
previous month
> (severity incorporated into higher score per item).
Most items can score a maximum of 3 points. Few
items can score a maximum of 1 point. The laboratory
category can score a maximum of 21 points.
Psychometric information
The SLAM-R index has been found to be reliable and
valid and to have an excellent sensitivity and responsiveness
to change over time [18]. The SLAM index correlates with
other disease activity measures, including the BILAG and
SLEDAI. The correlation between the SLAM-R scores,
the physician’s global assessment, anti-double-stranded
DNA, and C3 and C4 were statistically significant, ranging
from −0.29 to 0.87.
The reliability of SLAM was demonstrated with an
inter-rater reliability and an inter-visit reliability of 0.86
and 0.73, respectively, and findings for the SLAM-R
were similar (0.78 and 0.85, respectively). The validity of
the index was shown with a significant correlation be-
tween the SLAM and the other scales with an average
range of 0.9 to 1.0. Convergent validity was demon-
strated with an average range of 0.5 to 0.8 across
instruments.
Strength The SLAM index includes both dimensions: dis-
ease activity and disease severity. It gives equal weighting
to mild and serious organ disease activity without consid-
ering the significance of the organ involved.
Weakness One of the disadvantages of the SLAM index
is that many of its items are subjective, and much of the
scoring relies on the reporting of symptoms by the pa-
tients. SLAM may also have some difficulty in distin-
guishing a change, in particular when scoring minimally
active disease items versus damage.
Administrative burden A physician is to complete the
questionnaire, which is available in paper format or aspart of the BLIPS software program. The scoring is sim-
ple additive. The maximum score is 81 points. Judgment
as to whether manifestations (laboratory or otherwise)
are due to lupus is needed.
A complete history and physical examination are also
needed. It can take up to 15 minutes to complete the
form. Training is needed to develop consensus on subject-
ive components of the index, especially in multi-center
studies. There is no cost to use unless the computerized
version is needed; the cost then depends upon type of
usage (commercial/academic). There is a modest cost to
complete laboratory tests.
Responsiveness to patient concerns This index has a
high sensitivity to change and responsiveness when the
patient’s global assessment is considered to be the
standard. The SLAM correlates with several aspects of
the patient’s perception of health, as evaluated with the
36-Item Short Form Health Survey (SF-36).
Systemic lupus erythematosus disease activity index and
its versions
The SLEDAI is a global index that was developed and
introduced in 1985 as a clinical index for the assessment
of lupus disease activity in the preceding 10 days. It con-
sists of 24 weighted clinical and laboratory variables of
nine organ systems. This instrument was derived by con-
sensus among experts in rheumatology followed by ap-
plication of regression models to assign relative weights
to each parameter. SLEDAI was modeled on the basis of
clinician global judgment. The scores of the descriptors
range from 1 to 8, and the total possible score for all 24
descriptors is 105.
Safety of Estrogens in Lupus National Assessment
study-SLEDAI
A modified version of the SLEDAI (SELENA-SLEDAI)
was devised for use in the Safety of Estrogens in Lupus
National Assessment (SELENA) study. A glossary was
added, and the scoring was modified to account for per-
sistent active disease in some descriptors (rash, mucosal
ulcers, and alopecia), which were previously not scored
unless they were new or recurrent.
In the SELENA-SLEDAI, researchers accepted the
presence of either the objective or subjective findings to
score the descriptor as present [19]. The SELENA-
SLEDAI version awaits rigorous validation with other
measures related to disease activity in SLE.
SLEDAI-2000
SLEDAI-2000 (SLEDAI-2 K) was introduced in 2002 as
a measure of global disease activity. SLEDAI-2 K is a
modification of the original SLEDAI to allow the documen-
tation of persistent disease activity in the descriptors: rash,
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been validated against the classic SLEDAI, and proven to
be sensitive to change over time. SLEDAI is a strong pre-
dictor of mortality in SLE [20].
SLEDAI-2 K (30-day)
A 30-day extension of the SLEDAI-2 K was then tested
and demonstrated to be equivalent to the original 10-day
version [21, 22]. Descriptors of SLEDAI-2 K are docu-
mented as present or absent. Each of the descriptors has a
weighted score, and the total score of SLEDAI-2 K is the
sum of all 24 descriptor scores. The total SLEDAI-2 K score
falls between 0 and 105. A score of 6 is considered clinically
important and affects the decision to treat with a probabil-
ity of initiating therapy in more than 50 % of cases. Mean-
ingful improvement is best defined as a reduction in
SLEDAI-2 K of 4.
Psychometric information
The SLEDAI has demonstrated validity, reliability, and
sensitivity to change in several observational studies.
Lupus disease activity measured by SLEDAI has been a
major determinant of damage accrual and is highly predict-
ive of mortality within a 6-month period. The reliability of
the original SLEDAI was verified with an inter-rater correl-
ation ranging from 0.61 to 0.80 [2]. The reliability of the
SLEDAI-2 K was demonstrated with an agreement for each
of the items between 81.7 % and 100 % [3]. The SLEDAI val-
idity was verified with an ICC of 0.79 [2]. The SLEDAI-2 K
was validated against the SLEDAI with a high correlation
between both indices (r = 0.97, P = 0.0001) [20].
The SLEDAI sensitivity and responsiveness to change
have been shown in comparative studies with the SLAM,
BILAG, and European Consensus Lupus Activity Mea-
surements. The sensitivity to change was estimated to be
the smallest for the SLEDAI; the standardized response
means were 0.48 when the physician global assessment
was used as the standard and −0.01 when the patient
global assessment was used [10].
Strength All versions are validated and used by lupus
researchers for clinical and research purposes. The prac-
tical applicability of SLEDAI in clinical settings, its ease
of administration, and its simplicity in scoring are funda-
mental properties. SLEDAI-2 K is one of the most com-
monly used global disease activity measures in longitudinal
observational studies and clinical trials.
Weakness The SLEDAI versions do not capture im-
proving or worsening, do not include severity within an
organ system, and are less sensitive to change when
compared with other instruments. SLEDAI-2 K is a glo-
bal index that generates a total score reflecting an over-
all disease activity but is capable of measuring diseaseactivity in each of the nine organ systems if required.
The use of SLEDAI as a single determinant of flare or
worsening remains limited since worsening of pre-
existing symptoms and less-than-complete remission of
such symptoms (even with significant improvement) do
not change the SLEDAI score. The SELENA-SLEDAI
did provide a separate flare index.
Administrative burden SLEDAI must be completed by
a physician. It has a simple additive scoring system and
may take up to 10 minutes to complete. A complete his-
tory and physical examination are needed. The instru-
ment cannot be scored until laboratory results, including
immunological parameters, are available, and this may
take a few days. The Mexican modification of the SLE-
DAI, a simplified version without the immunologic test,
makes the index cheaper to administer. There is no
cost to use unless the computerized version is needed;
the cost then depends upon type of usage (commercial/
academic) [23].
Responsiveness to patient concerns Disease activity as
measured by SLEDAI does not significantly predict self-
reported levels of fatigue [24]. However, across five ran-
domized controlled trials in SLE, lower HRQOL scores at
baseline were highly correlated with higher disease activity
scores by SLEDAI or SELENA-SLEDAI or both [25].
Composite indices
The SLE responder index
The SLE Responder Index (SRI) is a composite outcome
that incorporates a modification of SELENA-SLEDAI,
BILAG, and a 3-cm visual analog scale of physician-
rated disease activity (PGA) to determine patient im-
provement [26]. The SRI was derived following post hoc
analysis of data from a phase II belimumab study in SLE
to identify subjects with a meaningful clinical improve-
ment in disease activity in response to treatment. The
SRI defines a responder as a patient whose disease
course fulfils all of the following: (1) at least a 4-point
reduction in SELENA-SLEDAI score; (2) no new BILAG
A (severe disease activity) or not more than one new
BILAG B (moderate disease activity) organ domain
score; and (3) no deterioration from baseline in the PGA
by at least 0.3 points (or 10 % of 3-point visual analog
scale) [27].
SLEDAI-2000 responder index 50
The SLEDAI-2000 Responder Index 50 (SRI-50) com-
prises the 24 SLEDAI-2 K descriptors, covering nine
organ systems, and generates a total score that reflects
disease activity over the previous 30 days as does
SLEDAI-2 K. Each of the SRI-50 descriptors identifies at
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corresponding descriptor [28].
Psychometric information
The SRI-50 has been shown to be reliable, valid, and su-
perior to SLEDAI-2 K in detecting partial clinical im-
provement (at least 50 %) between visits. The average
intra-rater reliability values of SLEDAI-2 K, SRI-50, and
PGA were 0.99, 0.98, and 0.90, respectively [29]. The
SRI-50 has been validated and has shown sensitivity re-
sponse prospectively at 6 and 12 months and retrospect-
ively at 10 years [30, 31].
Strength SRI-50 has been proven to be superior to the
SLEDAI-2 K in identifying patients with 50 % or greater
improvement. SRI-50 might improve and facilitate the
identification of responders in longitudinal research
studies.
Weakness The SRI uses SLEDAI to determine global
improvement, and an improvement in SLEDAI descriptors
is captured when a manifestation has completely resolved.
The SRI and SLEDAI share the same disadvantages by
missing the signal toward improvement. The SRI original
organ scoring is not weighted by severity but by overall
impact on disease.
Administrative burden SRI and SRI-50 require training
for optimal performance. Data retrieval forms have been
developed and posted on dedicated web sites that offer
training and examination modules for physicians and
trainees.
Responsiveness to patient concerns The SRI reported
clinically meaningful improvement that correlated with
all domain scores of SF-36 and the FACIT (Functional
Assessment of Chronic Illness Therapy) fatigue scores [32].
In addition, the partial improvement measured by SRI-50
was felt by the clinicians to reflect a clinically import-
ant improvement. Nonetheless, the effect size of the
original SRI (4-point drop in SLEDAI) is at best modest. It
remains unclear whether this effect size is the optimal
discriminatory endpoint that reflects responsiveness to
patient concerns.
The BILAG-Based Composite Lupus Assessment
The BILAG-Based Composite Lupus Assessment (BICLA)
is a composite index that was originally derived by expert
consensus of disease activity indices [33]. The BICLA
response was the primary endpoint in the EMBLEM
(Study of Epratuzumab in Serologically-positive Systemic
Lupus Erythematosus (SLE) Patients With Active Disease)
(NCT00624351), a 12 -week multicenter, phase IIb ran-
domized double-blind placebo-controlled trial that assessedthe efficacy and safety of epratuzumab in patients with
moderate-to-severe SLE disease activity. Requirement for
the BICLA response were: (1) BILAG-2004 improvement
(all A scores at baseline improved to B/C/D, and all B
scores improved to C or D); (2) no worsening in disease ac-
tivity (no new BILAG A or more than one new BILAG B
score); (3) no worsening of total SLEDAI-2 K score from
baseline; (4) no significant deterioration (<10 % worsening)
in physician’s global assessment; and (5) no treatment fail-
ure (initiation of non-protocol treatment) [34].Psychometric information
The SLEDAI and BILAG are the key drivers of the SRI
and the BICLA responders, and their sensitivity and re-
sponsiveness to change have been shown in comparative
studies with other lupus activity measurements. Direct
comparison of the SRI and the BICLA psychometric
properties requires caution because of the different
methodologies employed in the development and evalu-
ation of the clinical parameters contained in both indices.
Direct comparison between the BICLA and the SRI
composite endpoints has been addressed in few stud-
ies [35, 36]. Disagreement between BICLA and SRI is
observed, and is driven by a scoring issue. BICLA cri-
teria require a stringent response in all body systems
that are involved at baseline, and no new flares in the
remaining body system are allowed. This is compared
with SRI, in which a subject could qualify as a re-
sponder when a feature of SLEDAI resolves, while
other features (if present at baseline) stayed the same
or worsened slightly.
A similar analysis was applied to the data in the Bio-
markers of Lupus Disease (BOLD) study [36]. The BICLA
and SRI were compared with a simpler BOLD study re-
sponse criteria minimally defined by either a drop of at least
one BILAG grade or at least a 4-point reduction in SLEDAI
from baseline. BICLA was found to be superior to SRI in
detecting improvement and less likely to pick up flare visit.Administrative burden
BICLA is completed by a physician. A computer pro-
gram is needed to calculate categorical or numerical
scoring. Formal training of raters and a well-defined
glossary are required to ensure the optimal performance.Responsiveness to patient concerns
Epratuzumab treatment in the EMBLEM trial using the
BICLA showed clinically meaningful and sustained im-
provements in patient and physician global assessments
of disease activity, SF-36 and quality of life, and reduc-
tions in corticosteroid doses.
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Several lupus nephritis outcome measures have been
proposed and implemented, including the quantitative
change in urinary sediments, proteinuria, renal func-
tion, and adverse events with histopathology serving as
a case definition and, when relevant, as an additional
endpoint [37, 38]. Composite outcomes defined as im-
provement (complete response, partial response, or no
response), reduction in renal flares, or increase in time
to flare were adopted [39, 40]. A post hoc analysis of
the data from the abatacept trial highlighted the response
criteria from different nephritis trials [41]. Given the
current poor prognosis for the renal disease, a consensus-
derived lupus nephritis response document is urgently
needed, generally on the basis of trivial administrative
burden.
Similarly, the Cutaneous Lupus Erythematosus Dis-
ease Area and Severity Index (CLASI) and the revised
CLASI, a comprehensive tool for assessment of disease
activity and damage in cutaneous lupus, were shown to
be valid, reliable, and sensitive to changes in disease ac-
tivity [42–44]. Nonetheless, CLASI scoring is heavily
influenced by the number of areas involved rather than
the coverage of skin within each area, and higher
weighting of visible areas tends to cause greater patient
impairment. CLASI has demonstrated validity by der-
matologists and rheumatologists and is responsive to
patient-reported measures.Measuring SLE flares
Several studies have attempted to define flare, including
time to flare, numbers of flares, and severity of flares.
Optimal SLEDAI cutoffs for active disease and flare, based
on a physician’s expert opinion, have been examined. Flare
was defined as a 4-point increase in SLEDAI-2 K.
The SELENA-SLEDAI Flare Index (SFI), developed by
the SELENA trials, is a composite outcome of SELENA-
SLEDAI; mild, moderate, and severe flares; and the PGA
of disease activity [7]. The revised SFI suggests specific
clinical manifestations for each organ system and cate-
gorizes flares into mild, moderate, and severe on the
basis of the treatment decision.Note: This article is part of the series ‘Measuring meaningful
change in lupus clinical trials’, edited by Matthew Liang and
Chan-Bum Choi. Other articles in this series can be found at
http://arthritis-research.com/series/trialsThe BILAG-2004 flare index
A composite BILAG-2004 flare index has been proposed
with flares determined by the number of systems scoring A
or B due to items recorded as new or worse [45]. A severe
flare is defined as the occurrence of at least one such A
score, a moderate flare as the occurrence of at least two
such B scores, and a mild flare as the occurrence of one B
or at least three such C scores in separate systems.
Guidelines for scoring of worsening in the renal and
hematologic domains are not yet available. Contrary to theSFI, selection of treatment does not override the clinical de-
scriptors chosen.
When compared with the SFI and the physician’s global
assessment, the BILAG-2004 flare index showed the
highest inter-rater reliability. There was good agree-
ment between the indices when distinguishing flares
and no flares but much less consistency with mild to
moderate flares. A definition of flare has been proposed
by a formal Delphi consensus process. The clinical
judgment of the physician is emphasized for determin-
ation of a flare, which indicates a significant change in
disease activity [46].Conclusions
The judgment of whether a patient with SLE is better
or worse is a central question in patient management.
After the failure of several clinical trials of biologic
therapy in SLE, the management of SLE today remains
an art rather than a science. The objective is to improve
disease state or at least fend off its deterioration, be
accurate in defining disease activity and flare state,
and employ evidence-based and clinically meaningful
response criteria measured with valid and reproducible
instruments that are sensitive to change and responsive
to a patient’s concerns.
Pitfalls in lupus disease activity measures have had a sig-
nificant impact on the interpretation of study outcomes.
Many of the clinical trials were overpowered or underpow-
ered and had complex and multiple outcome measures.
Devised in the 1990s, these metrics were never intended for
use in clinical trials. This underlines the importance for im-
proving these instruments and optimizing on the composite
indices for ascertainment of disease activity. Nonetheless, in
the absence of a biomarker-based gold standard against
which to gauge improvement or flare, selection of SLE dis-
ease endpoints should be defined and tailored to the out-
come of interest. Moreover, the exact choice of disease
activity-measuring instruments should be governed by the
purpose for which they are required in clinical research.
They should be simple, reliable, and valid with reduced
administrative burden, which may integrate elements for
enhanced responsiveness to patient concerns by using the
platform by the published FDA guidance document. It is
essential to make certain that disease activity measures are
being applied consistently and uniformly through proper
and simple training, given the potential complexity of
patients with different SLE manifestations.
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